Satellos Bioscience Inc (0ITA.BE)

Compare

0.6550

+0.0150

(+2.34%)

As of 6:46:04 PM GMT+1. Market Open.

Satellos doses first DMD subject in Phase Ib trial

The Phase I clinical trial of SAT-3247 is structured in two components.

Clinical Trials Arena 4 days ago

MSCLF
Satellos Announces First Participant with Duchenne Muscular Dystrophy Dosed in the Phase 1b Clinical Trial of SAT-3247

TORONTO, December 11, 2024--Satellos Bioscience Inc. (TSX: MSCL, OTCQB: MSCLF) ("Satellos" or the "Company"), a public biotech company developing new small molecule therapeutic approaches to improve the treatment of muscle diseases and disorders, announced today that the first participant with Duchenne muscular dystrophy ("DMD") has been dosed in the Phase 1b safety and pharmacokinetics ("PK") trial in DMD patients.

Business Wire 5 days ago

MSCLF
December 2024's Top TSX Penny Stocks To Watch

As the Canadian market benefits from easing monetary policies and strong fundamentals in sectors like financials and materials, investors are exploring diverse opportunities for growth. Penny stocks, though an older term, continue to represent a compelling investment area by offering access to smaller or newer companies poised for potential growth. By focusing on those with robust financial health and clear growth trajectories, investors can uncover promising opportunities within this niche...

Simply Wall St. 11 days ago

MSCLF

BEWFF

ORFDF
Satellos to Participate in Oppenheimer Movers in Rare Disease Summit

TORONTO, December 03, 2024--Satellos Bioscience Inc. (TSX:MSCL, OTCQB:MSCLF) ("Satellos"), a public biotech company developing new small molecule therapeutic approaches to improve the treatment of muscle diseases and disorders, announced today that Frank Gleeson, Co-founder and CEO will participate in Oppenheimer’s Movers in Rare Disease Summit taking place in New York City on December 12, 2024.

Business Wire 13 days ago

MSCLF
Satellos to Participate in Duchenne KOL Investor Webinar on December 4, 2024

TORONTO, December 02, 2024--Satellos Bioscience Inc. (TSX:MSCL, OTCQB:MSCLF) ("Satellos" or the "Company"), a public biotech company developing new small molecule therapeutic approaches to improve the treatment of muscle diseases and disorders, today announced participation in a live investor webinar (the "Webinar") focused on a discussion of Duchenne muscular dystrophy ("DMD") by Key Opinion Leaders ("KOLs") in the space.

Business Wire 14 days ago

MSCLF
Satellos Appoints Stephanie Brown to Board of Directors

TORONTO, November 14, 2024--Satellos Bioscience Inc. (TSX: MSCL) (OTCQB: MSCLF) ("Satellos" or the "Company"), a public biotech company developing new small molecule therapeutic approaches to improve the treatment of muscle diseases and disorders, announced today the appointment of Stephanie Brown to its Board of Directors. Ms. Brown brings over 30 years of biopharma industry experience, having held numerous executive roles contributing to groundbreaking achievements in product commercialization

Business Wire last month

MSCLF
Satellos Bioscience: Q3 Earnings Snapshot

TORONTO (AP) — Satellos Bioscience Inc. MSCLF) on Wednesday reported a loss of $6.6 million in its third quarter. The Toronto-based company said it had a loss of 6 cents per share.

Associated Press Finance last month

MSCLF
Satellos Reports Q3 2024 Financial Results and Provides Clinical Update

TORONTO, November 13, 2024--Satellos Bioscience Inc. (TSX: MSCL, OTCQB: MSCLF) ("Satellos" or the "Company"), a clinical-stage biotechnology company developing life-improving medicines to treat degenerative muscle diseases, announced today its financial results and corporate highlights for the three months ended September 30, 2024. All references to currency in this press release are in Canadian dollars unless otherwise noted.

Business Wire last month

MSCLF
Satellos to Participate in November 2024 Investor Conferences

TORONTO, November 04, 2024--Satellos Bioscience Inc. ("Satellos" or the "Company") (TSX: MSCL) (OTCQB: MSCLF), a public biotech company developing new small molecule therapeutic approaches to improve the treatment of muscle diseases and disorders, announced today that members of the management team of the Company will participate in the following investor conferences.

Business Wire last month

MSCLF
Spotlight On 3 TSX Penny Stocks With Market Caps Over CA$90M

The Canadian market has shown impressive growth, climbing 1.4% over the last week and 28% over the past year, with earnings expected to grow by 16% annually in the coming years. For investors willing to look beyond well-known companies, penny stocks—often representing smaller or newer enterprises—can present intriguing opportunities. Although 'penny stock' might seem like an outdated term, these investments remain relevant today as they can offer hidden value and potential for substantial...

Simply Wall St. last month

MSCLF

WONDF

ELEMF
Here's Why We're Watching Satellos Bioscience's (TSE:MSCL) Cash Burn Situation

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...

Simply Wall St. 2 months ago

MSCLF
Satellos to Present Data on SAT-3247 Pilot Study at World Muscle Society Meeting

Satellos to Present Data on SAT-3247 Pilot Study at World Muscle Society Meeting

PREMIUM
MT Newswires 2 months ago

MSCLF
Satellos Demonstrates Treatment of DMD Canines with SAT-3247 Improved Measures of Strength to Near Normal Levels

TORONTO, October 01, 2024--Satellos Bioscience Inc. ("Satellos" or the "Company") (TSX: MSCL, OTCQB: MSCLF), a public biotech company developing new small molecule therapeutic approaches to improve the treatment of muscle diseases and disorders, today announced a presentation of data at the 29th Annual Congress of the World Muscle Society taking place October 8-12, 2024, in Prague. The presentation will provide an overview of key data collected during the open-label pilot study of SAT-3247 in a

Business Wire 2 months ago

MSCLF
Satellos Bioscience doses first subject in Phase I trial of SAT-3247

Initial safety and pharmacokinetic data from the trial are expected in Q4 2024.

Clinical Trials Arena 2 months ago

MSCLF
Satellos Announces Dosing of First Participant in Phase 1 Clinical Study of SAT-3247

TORONTO, September 18, 2024--Satellos Bioscience Inc. ("Satellos" or the "Company") (TSX: MSCL) (OTCQB: MSCLF), a public biotech company developing new small molecule therapeutic approaches to improve the treatment of muscle diseases and disorders, announced today that the first participant has been dosed in a Phase 1 clinical study of SAT-3247. SAT-3247 is a novel, oral small molecule drug targeting AAK1 that is designed to regenerate skeletal muscle in Duchenne muscular dystrophy (DMD or Duche

Business Wire 2 months ago

MSCLF
Satellos Announces Participation in September 2024 Investor Conferences

TORONTO, September 05, 2024--Satellos Bioscience Inc. ("Satellos" or the "Company") (TSX: MSCL) (OTCQB: MSCLF), a public biotech company developing new small molecule therapeutic approaches to improve the treatment of muscle diseases and disorders, announced today that Mr. Frank Gleeson, Co-founder and CEO of Satellos will participate in fireside chats and one-on-one meetings during the following conferences taking place in New York City along with Ms. Elizabeth Williams, CFO of Satellos.

Business Wire 3 months ago

MSCLF
MSCLF: SAT-3247 Enhances Muscle Repair in Canine Model of DMD…

By David Bautz, PhD OTC:MSCLF READ THE FULL MSCLF RESEARCH REPORT Business Update SAT-3247 Enhances Muscle Repair in Canine DMD Model On August 12, 2024, Satellos Biosciences Inc. (OTC:MSCLF) announced new results from a canine model of Duchenne muscular dystrophy (DMD). The following figure gives an overview of the study, which utilized two eight-month-old dogs with genetically confirmed

Zacks Small Cap Research 3 months ago

MSCLF
Satellos Bioscience Given Go-ahead for Phase 1 Clinical Trial With SAT-3247 in Australia

Satellos Bioscience Given Go-ahead for Phase 1 Clinical Trial With SAT-3247 in Australia

PREMIUM
MT Newswires 3 months ago

MSCLF
Satellos Announces Acceptance of Regulatory Filing to Commence a Phase 1 Clinical Trial with SAT-3247

TORONTO, August 19, 2024--Satellos Bioscience Inc. ("Satellos" or the "Company") (TSX: MSCL, OTCQB: MSCLF), a public biotech company developing new small molecule therapeutic approaches to improve the treatment of muscle diseases and disorders, today announced acceptance of a clinical research proposal to a Human Research Ethics Committee (HREC) in Australia seeking regulatory authorization under their Therapeutic Goods Administration’s (TGA’s) Clinical Trial Notification (CTN) scheme to conduct

Business Wire 3 months ago

MSCLF
Satellos Bioscience: Q2 Earnings Snapshot

TORONTO (AP) — Satellos Bioscience Inc. MSCLF) on Monday reported a loss of $4.4 million in its second quarter. On a per-share basis, the Toronto-based company said it had a loss of 4 cents.

Associated Press Finance 4 months ago

MSCLF

Performance Overview

Return	0ITA.BE	S&P/TSX Composite index
YTD	+129.02%	+20.08%
1-Year	+96.11%	+22.59%
3-Year	-13.25%	+21.17%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Satellos Bioscience Inc (0ITA.BE)

Satellos doses first DMD subject in Phase Ib trial

Satellos Announces First Participant with Duchenne Muscular Dystrophy Dosed in the Phase 1b Clinical Trial of SAT-3247

December 2024's Top TSX Penny Stocks To Watch

Satellos to Participate in Oppenheimer Movers in Rare Disease Summit

Satellos to Participate in Duchenne KOL Investor Webinar on December 4, 2024

Satellos Appoints Stephanie Brown to Board of Directors

Satellos Bioscience: Q3 Earnings Snapshot

Satellos Reports Q3 2024 Financial Results and Provides Clinical Update

Satellos to Participate in November 2024 Investor Conferences

Spotlight On 3 TSX Penny Stocks With Market Caps Over CA$90M

Here's Why We're Watching Satellos Bioscience's (TSE:MSCL) Cash Burn Situation

Satellos to Present Data on SAT-3247 Pilot Study at World Muscle Society Meeting

Satellos Demonstrates Treatment of DMD Canines with SAT-3247 Improved Measures of Strength to Near Normal Levels

Satellos Bioscience doses first subject in Phase I trial of SAT-3247

Satellos Announces Dosing of First Participant in Phase 1 Clinical Study of SAT-3247

Satellos Announces Participation in September 2024 Investor Conferences

MSCLF: SAT-3247 Enhances Muscle Repair in Canine Model of DMD…

Satellos Bioscience Given Go-ahead for Phase 1 Clinical Trial With SAT-3247 in Australia

Satellos Announces Acceptance of Regulatory Filing to Commence a Phase 1 Clinical Trial with SAT-3247

Satellos Bioscience: Q2 Earnings Snapshot

Performance Overview